Investment, Funding & Disinvestments

The merger has already cleared several regulatory hurdles, having secured approval from the Competition Commission of India (CCI) and received ‘No Objection’ letters from the Stock Exchanges.

The grant will enable Qure.ai to develop a comprehensive open-source multi-modal database designed to accelerate future prevention and identification innovations.

The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.

This move introduces advanced tools like the da Vinci robotic surgical system, promising to elevate medical care across the region.

Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.

President Donald Trump initiated this process exactly one year ago when he signed an executive order on his first day in office in 2025, pointing to what he described as the organization’s “mishandling of the COVID-19 pandemic” and its response to “other global health crises.”

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

The plant is scheduled to begin operations by 2029 and will focus on producing cutting-edge treatments for metabolic conditions, particularly obesity medications.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.